Raising heart failure medication doses with careful kidney checks
Part of Heart & circulation clinical trials.
This trial tests whether safely increasing the dose of standard heart failure medications can improve outcomes in people with a weak heart pump, while keeping a close eye on kidney function. It may be a good fit if you have heart failure with reduced ejection fraction and are not yet on the highest recommended doses of your medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with heart failure with reduced ejection fraction (a weak heart pump).
- You are not yet on the full recommended dose of certain heart failure medicines (ACE inhibitors, ARBs, ARNI, MRAs, or SGLT2 inhibitors).
- Your recent kidney function test (eGFR) shows your kidneys are working at least moderately well (not too low).
- You do not have severe kidney disease or signs of unstable heart failure (like needing IV diuretics).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether patients whose heart failure has improved can safely reduce some of their medications. If your heart function has recovered significantly and stayed stable, this trial explores whether you can gradually lower doses of heart failure drugs while staying healthy.
This study looks at whether patients with severe heart failure follow their prescribed medications as recommended by treatment guidelines. The researchers want to understand what helps or prevents patients from taking their medicines correctly, which could improve their heart function and symptoms.
This study tests a personalized approach to safely increase the dose of your heart failure medication (beta-blocker). It aims to improve your symptoms and overall heart function by tailoring the dose to your specific needs.
This trial tests whether adjusting heart failure medications in women can improve their recovery and outcomes. It focuses on women who have been recently hospitalized for acute heart failure and are not yet on optimal medication doses.
This study tests an experimental medicine, CDR132L, to see if it can improve heart structure and function in people with a type of heart failure where the heart muscle is thickened. If you have heart failure with normal pumping function and thickened heart walls, this trial may offer access to a new potential treatment.
This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.